Featured Content

  • Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer Cellceutix Corporation (OTC: CTIX), reports, based upon ongoing laboratory studies, the Company intends to use docetaxel for the .add_link li a{width: 105px; color:#0098c8; font:normal 16px/32px "宋体"; height:32px; overflow:hidden; display:inline-block; margin: 0 0 0 12px;} combination therapy arm in the .add_link li a:hover{ text-decoration:underline;} planned Phase 2 clinical trial to treat patients with platinum-resistance ovarian cancer. Cellceutix is designing the .boxbg { multi-arm study to evaluate Kevetrin as a monotherapy and U.S. Food and Drug Administration (FDA) has approved Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the


    128183000:2016-04-30 23:02:59 first TAF-based regimen to receive FDA approval.
More News

Sector News

More News

More Articles...

News and Analysis

  • Come Join Our Commuity We are offering discounted subscription plans to join BioMedReports.com for a limited time.
  • Q&A with LabStyle Innovations Exec VP, Todd Durniak Recently, LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, announced it had closed a round of funding totaling approximately $2.5 million. According to management, the monies will be used to support the global rollout and .add_link li{ float: left; } initial U.S. commercial launch of their flagship product Dario™ for working capital purposes.
More News


BioMedReports Q BioMed's CEO featured in article he wrote titled Accelerators Enter When VCs Fear To Tread: https://t.co/NuOXexgSaY $QBIO
BioMedReports DiaMedica Completes Issue of Shares for Debt to BFC Group: https://t.co/PbNeO3NBAF $DMCAF
BioMedReports AstraZeneca Beefs Up Immuno-Oncology Pipeline with TapImmune Technology: https://t.co/zvvP1grhgr $TPIV

RSS Subscription